文献速递血栓与止血

CD44抗体通过抑制Fcγ受体在鼠免疫性血小板减少症中发挥抗炎作用

Anti-inflammatory activity of CD44 antibodies in murine immune thrombocytopenia is mediated by Fcγ receptor inhibition.
PubMed 文献 · Blood · 2021-01-01

该研究在小鼠免疫性血小板减少症(ITP)模型中探索CD44单克隆IgG抗体的抗炎机制。体外实验显示CD44抗体通过阻断FcγR的IgG结合位点抑制巨噬细胞对IgG调理血小板的吞噬,且该作用依赖抗体Fc段。体内实验证实CD44抗体通过阻断FcγR保护小鼠免于ITP,Fc失活变异体完全无效,提示CD44抗体可作为IVIg替代品。

要点

  • CD44抗体通过阻断巨噬细胞FcγR的IgG结合位点抑制吞噬,不改变FcγR表面表达。
  • CD44抗体的Fc段是其抑制FcγR功能及缓解ITP所必需的。
  • CD44抗体在鼠ITP中通过FcγR阻断机制发挥作用,有望成为IVIg替代品。

核心结论

  • CD44抗体通过抑制巨噬细胞FcγR功能、阻断FcγR的IgG结合位点,在鼠ITP中发挥抗炎作用并改善疾病。

研究设计与样本

  • 研究采用小鼠免疫性血小板减少症(ITP)模型,包括被动ITP模型,并进行体外巨噬细胞吞噬实验。

主要发现

  • 体外实验中,CD44抗体处理的巨噬细胞对IgG调理的血小板和红细胞的FcγR介导吞噬作用显著受抑。
  • CD44抗体对FcγR的阻断具有亚类特异性,仅针对相应亚类可结合的FcγR,Fc失活变异体丧失全部FcγR抑制活性。
  • 体内被动ITP模型中,CD44抗体通过其亚类可结合的FcγR发挥保护作用,Fc失活变异体完全不能改善ITP。

临床怎么用

  • CD44抗体可能作为IVIg的替代方案用于ITP治疗,尤其考虑到FcγR在人类ITP病理生理中的重要作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Monoclonal immunoglobulin G (IgG) antibodies to CD44 (anti-CD44) are anti-inflammatory in numerous murine autoimmune models, but the mechanisms are poorly understood. Anti-CD44 anti-inflammatory activity shows complete therapeutic concordance with IV immunoglobulin (IVIg) in treating autoimmune disease models, making anti-CD44 a potential IVIg alternative. In murine immune thrombocytopenia (ITP), there is no mechanistic explanation for anti-CD44 activity, although anti-CD44 ameliorates disease similarly to IVIg. Here, we demonstrate a novel anti-inflammatory mechanism of anti-CD44 that explains disease amelioration by anti-CD44 in murine ITP. Macrophages treated with anti-CD44 in vitro had dramatically suppressed phagocytosis through FcγRs in 2 separate systems of IgG-opsonized platelets and erythrocytes. Phagocytosis inhibition by anti-CD44 was mediated by blockade of the FcγR IgG binding site without changing surface FcγR expression. Anti-CD44 of different subclasses revealed that FcγR blockade was specific to receptors that could be engaged by the respective anti-CD44 subclass, and Fc-deactivated anti-CD44 variants lost all FcγR-inhibiting activity. In vivo, anti-CD44 functioned analogously in the murine passive ITP model and protected mice from ITP when thrombocytopenia was induced through an FcγR that could be engaged by the CD44 antibody's subclass. Consistent with FcγR blockade, Fc-deactivated variants of anti-CD44 were completely unable to ameliorate ITP. Together, anti-CD44 inhibits macrophage FcγR function and ameliorates ITP consistent with an FcγR blockade mechanism. Anti-CD44 is a potential IVIg alternative and may be of particular benefit in ITP because of the significant role that FcγRs play in human ITP pathophysiology.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Norris PAA, Kaur G, Khan R, et al. Anti-inflammatory activity of CD44 antibodies in murine immune thrombocytopenia is mediated by Fcγ receptor inhibition. Blood. 2021. PMID: 33662988. doi:10.1182/blood.2020009497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。